TiumBio Co., Ltd. (KOSDAQ:321550)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,120.00
-20.00 (-0.39%)
Last updated: Jun 27, 2025
-8.41%
Market Cap 143.85B
Revenue (ttm) 6.91B
Net Income (ttm) -21.12B
Shares Out 26.99M
EPS (ttm) -806.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,053
Average Volume 146,633
Open 5,140.00
Previous Close 5,140.00
Day's Range 5,010.00 - 5,180.00
52-Week Range 2,900.00 - 7,260.00
Beta 0.62
RSI 39.00
Earnings Date Aug 14, 2025

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. TiumBio Co., Ltd. was founded in 2016 and is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 68
Stock Exchange KOSDAQ
Ticker Symbol 321550
Full Company Profile

Financial Performance

In 2024, TiumBio's revenue was 6.79 billion, an increase of 38.65% compared to the previous year's 4.90 billion. Losses were -20.64 billion, 15.3% more than in 2023.

Financial Statements

News

There is no news available yet.